Skip to content

Research at St Andrews

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes indicative of pathway activation that might link with drug response. Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used. Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment was measured by quantitative immunofluorescence and analysed by AQUA . Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR and DDR pathways, while at late time points WNT, invasion , EMT and MAPK pathways were modulated. Estrogen receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24h from treatment administration. Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced changes than with carboplatin alone . In addition to expression of pS6 and pERK increasing, components of the AKT pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling, EMT and invasion markers were modulated at later time points. Additional pathways were also observed with the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further protein members of the ERB B pathway were upregulated late. By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.
Close

Details

Original languageEnglish
Article number205
Number of pages13
JournalBMC Cancer
Volume16
DOIs
Publication statusPublished - 10 Mar 2016

    Research areas

  • Ovarian cancer, Carboplatin, Pacltaxel, Xenograft, Prognosis, Phosphoproteins

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system

    Koussounadis, A., Langdon, S., Um, I. H., Harrison, D. J. & Smith, V. A., 8 Jun 2015, In: Scientific Reports. 5, 9 p., 10775.

    Research output: Contribution to journalArticlepeer-review

  2. Tissue-specific Immunopathology in Fatal COVID-19

    ICECAP consortium, Um, I. H., Elshani, M. & Harrison, D. J., 20 Nov 2020, In: American Journal of Respiratory and Critical Care Medicine.

    Research output: Contribution to journalArticlepeer-review

  3. Computerized image analysis of tumor cell nuclear morphology can improve patient selection for clinical trials in localized clear cell renal cell carcinoma

    Um, I. H., Scott-Hayward, L., MacKenzie, M. L., Tan, P. H., Kanesvaran, R., Choudhury, Y., Caie, P. D., Tan, M-H., O'Donnell, M., Leung, S., Stewart, G. & Harrison, D. J., 6 Nov 2020, In: Journal of Pathology Informatics. 11, 8 p., 35.

    Research output: Contribution to journalArticlepeer-review

  4. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models

    Langdon, S. P., Kay, C., Um, I. H., Muir, M., Sellar, G., Kan, J., Gourley, C. & Harrison, D. J., 10 Dec 2019, In: Scientific Reports. 9, 9 p., 18742.

    Research output: Contribution to journalArticlepeer-review

  5. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In: Scientific Reports. 9, 13 p., 7643.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer

    Yang, Y., Cameron, J., Bedi, C. & Humphris, G., 20 Oct 2018, In: BMC Cancer. 18, 9 p., 1002.

    Research output: Contribution to journalArticlepeer-review

  2. Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial

    Rogers, S. N., Lowe, D., Lowies, C., Yeo, S. T., Allmark, C., Mcavery, D., Humphris, G. M., Flavel, R., Semple, C., Thomas, S. J. & Kanatas, A., 18 Apr 2018, In: BMC Cancer. 18, 10 p., 444.

    Research output: Contribution to journalArticlepeer-review

  3. Serum and blood based biomarkers for lung cancer screening: a systematic review

    Chu, G. C. W., Lazare, K. & Sullivan, F., 13 Feb 2018, In: BMC Cancer. 18, 6 p., 181.

    Research output: Contribution to journalReview articlepeer-review

  4. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

    Gremel, G., Djureinovic, D., Niinivirta, M., Laird, A., Ljungqvist, O., Johannesson, H., Bergman, J., Edqvist, P-H., Navani, S., Khan, N., Patil, T., Sivertsson, Å., Uhlén, M., Harrison, D. J., Ullenhag, G. J., Stewart, G. D. & Pontén, F., 4 Jan 2017, In: BMC Cancer. 17, 9 p., 9.

    Research output: Contribution to journalArticlepeer-review

ID: 241226118

Top